The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Avoiding a second trial, a former pharmaceutical rep who prosecutors said generated more than $10 million in wrongful insurance reimbursements pleaded guilty Tuesday to perjury in U.S. District Court.

The owner of Fallon Wellness Pharmacy is relocating her business to accommodate growing demand for custom prescription medications—known as compound pharmaceuticals—for human and animal clients who ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...